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Background
When HIV-1 envelope glycoproteins bind to CD4, confor-
mational changes expose a site where the co-receptor can
bind. Epitopes associated with this site are known as CD4-
induced (CD4i) and give rise to antibodies which neutral-
ize a wide range of HIV-1 isolates. Immunogens can be
engineered to present these epitopes. Here, we show that
exposure to soluble CD4 also sensitises pseudovirus to
allow cross-neutralization of heterologous isolates by
antibodies elicited by trimeric glycoproteins that have not
been specifically modified to expose CD4i sites.
Methods
Sera were taken at six weeks after the final immunization
of rhesus macaques with trimeric recombinant HIV-1
envelope glycoproteins from HIV-1 461 (subtype A), HIV-
1 SF162 (subtype B) and/or HIV-1 TV1 (subtype C) and
have not been further engineered to enhance exposure of
CD4i epitopes. SHIVSF62P4, SHIVSF62P3, SHIVKB9 (≡
SHIV89.6P, subtype B), HIV-1 TV1 or HIV-1 MJ4 (subtype
C) pseudoviruses were exposed for 1 hour to sufficient
soluble CD4 to reduce their infectivity by 50%. Dilutions
of sera were then added to these mixtures and subse-
quently incubated for a further hour at 37°C before expo-
sure to TZMbl cells. After 48 hours in culture the
production of luciferase was quantified. Similar assays
were performed with monoclonal antibodies.
Results
Sera from immunized macaques neutralized homologous
SHIVSF162P4 or HIV-1 TV1 pseudoviruses but not heter-
ologous SHIV KB9 or HIV-1 MJ4. If the pseudovirus is first
exposed to soluble CD4 there is no increase in the neutral-
ization titre against homologous isolates. However, the
heterologous isolates are neutralized. A similar sensitiza-
tion of neutralization was seen with monoclonal antibod-
ies to the V3 region (447-52D) or gp41 (4E10).
Conclusion
Recombinant HIV-1 envelope glycoproteins induce anti-
bodies which neutralize homologous pseudoviruses.
However, the same immunogens also induce antibodies
which can cross-neutralize heterologous isolates provided
these have been pre-exposed to soluble CD4.
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